DDInter1568 DDInter1658
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Ranitidine {u} (Compound) resembles {v} (Compound) Nizatidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
Ranitidine {u} (Compound) upregulates {v} (Gene) GPATCH8
Ranitidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Ranitidine {u} (Compound) downregulates {v} (Gene) SDC1
Ranitidine {u} (Compound) causes {v} (Side Effect) Weight decreased
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etodolac
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tubocurarine
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Ranitidine (Compound) resembles Nizatidine (Compound)
Ranitidine (Compound) binds CYP3A4 (Gene)
Ranitidine (Compound) upregulates GPATCH8 (Gene)
Ranitidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Ranitidine (Compound) downregulates SDC1 (Gene)
Ranitidine (Compound) causes Weight decreased (Side Effect)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etodolac
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Tubocurarine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline